SK Biopharmaceuticals Co., Ltd. (KRX:326030)

SK Biopharmaceuticals Ratios and Metrics

Market cap in millions KRW. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Nov 6, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	9,358,433	8,700,602	7,862,650	5,646,385	7,612,048	13,234,939
Market Cap Growth	9.53%	10.66%	39.25%	-25.82%	-42.48%	-
Enterprise Value	9,229,653	8,637,734	7,807,605	5,442,304	7,267,516	12,840,764
Last Close Price	119500.00	111100.00	100400.00	72100.00	97200.00	169000.00
PE Ratio	36.56	36.14	-	-	117.39	-
Forward PE	41.30	73.81	-	-	-	-
PS Ratio	15.09	15.89	22.16	22.94	18.18	509.06
PB Ratio	15.24	15.16	24.50	17.84	17.14	34.92
P/TBV Ratio	15.94	16.24	29.59	18.86	17.90	36.83
P/FCF Ratio	92.66	93.05	-	-	-	-
P/OCF Ratio	90.66	91.68	-	-	-	-
EV/Sales Ratio	14.88	15.77	22.00	22.11	17.36	493.89
EV/EBITDA Ratio	72.64	75.93	-	-	68.18	-
EV/EBIT Ratio	84.42	89.66	-	-	76.53	-
EV/FCF Ratio	91.39	92.38	-	-	-	-
Debt / Equity Ratio	0.12	0.32	0.56	0.49	0.04	0.05
Debt / EBITDA Ratio	0.45	1.62	-	-	0.15	-
Debt / FCF Ratio	0.74	1.97	-	-	-	-
Asset Turnover	0.70	0.62	0.51	0.38	0.73	0.08
Inventory Turnover	0.36	0.40	0.35	0.53	0.60	0.13
Quick Ratio	1.54	1.26	1.47	2.28	2.64	5.67
Current Ratio	2.19	1.64	2.02	2.99	3.18	6.16
Return on Equity (ROE)	49.08%	50.72%	-11.10%	-36.66%	15.75%	-135.18%
Return on Assets (ROA)	10.38%	6.84%	-3.38%	-12.53%	10.38%	-46.83%
Return on Capital (ROIC)	14.56%	9.58%	-4.83%	-17.57%	13.84%	-60.65%
Return on Capital Employed (ROCE)	21.40%	15.00%	-	-	19.20%	-
Earnings Yield	2.74%	2.77%	-0.42%	-2.47%	0.85%	-1.87%
FCF Yield	1.08%	1.07%	-1.23%	-2.92%	-1.28%	-1.68%
Buyback Yield / Dilution	-	-	-	-	-9.12%	-10.41%

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.